Oncology Drug Discovery

Leaders in Cancer Drug Discovery | Johns Hopkins Medicine

Ross Donehower, one of the Cancer Center's first medical oncologists and a drug discovery researcher.

Drug Discovery | Center for Cancer Research

The Comparative Brain Tumor Consortium is collaborating with National Center for Advanced Translational Sciences to complete a high-throughput drug cell ...

Global Cancer Drug Development—A Report From the 2022 ...

In September 2022, the Accelerating Anticancer Agent Development and Validation workshop was held, focusing on global cancer drug development.

Emerging concepts in drug discovery for cancer therapy - PMC

Genotoxic chemotherapies were the first chemical cancer therapies to be developed, and are still one of the most widely used strategies for the ...

Drug discovery | Nature Reviews Clinical Oncology

The FDA calls for radical changes in the design of early phase trials to identify the optimal doses of oncology drugs to achieve maximal efficacy.

Experts Forecast 2024, Part 4: Oncology Drug Discovery | AACR

In 2024, he predicts that rapid advances in artificial intelligence (AI), chemical technology, and small-molecule chemical probes or tools will provide the ...

Advancing cancer drug discovery through collaboration and ...

An increased understanding of the underlying mechanisms of cancer, cutting-edge technologies, and a seismic cultural shift toward a collaborative team ...

LLNL and BridgeBio announce trials for supercomputing-discovered ...

In a milestone for supercomputing-aided drug design, Lawrence Livermore National Laboratory and BridgeBio Oncology Therapeutics today announced ...

The potential for AI to change cancer drug discovery and development

With rarer forms of disease, including some of the hardest-to-treat cancers, the potential for AI to impact drug discovery and development holds ...

Cancer drug development yesterday, today and tomorrow - PMC

Great progress in cancer therapy has been made thanks to the combined impact of better supportive care, ever improving drugs and earlier cancer detection.

Oncology 2020: a drug development and approval paradigm

The central philosophy behind this concept is that we need to move drug development from a series of linear, landmark events to a flexible and iterative process ...

Cancer Drug Discovery & Development Accelerator

The CD3A is an initiative of the cancer center with the goal of accelerating drug discovery and development by bringing together university researchers, ...

Cancer Drug Development - an overview | ScienceDirect Topics

Anti-cancer drug development is a major research field [1–3] on account of the drug-resistance, immune escape and metastasis of cancer cells that greatly limit ...

"DrugMap" Expected to Accelerate Cancer Drug Discovery

DrugMap is expected to provide a basis for investigations to better understand cysteine liganding, identify potential new therapeutic targets, ...

Drug discovery and therapeutic innovation - The Institute of Cancer ...

Since 2005, 10 of our drugs have entered clinical trials, and many more current cancer medicines are rooted in discoveries made here. The key to our success ...

Drug Discovery, Delivery & Experimental Therapeutics

To bring promising new cancer treatments and diagnostics to patients, members of the Drug Discovery, Delivery and Experimental Therapeutics research program ...

Drug Discovery Award | The Mark Foundation for Cancer Research

Award Details · Applicants may request funding to support a total budget of up to $1,000,000 for a period of 12-36 months. · The budget limit includes both ...

Immuno-Oncology Landscape - Cancer Research Institute

Landscape of Immuno-Oncology Drug Development. With an unprecedented number of new investigational agents and companies in immuno-oncology (IO), it has been ...

Cancer Drug Discovery: A Molecular Journey to Targeted Treatment

Cancer drug discovery has made great advances since its earliest steps. Cytotoxic drugs affect healthy cells, as well as the tumor, ...

Harnessing the predictive power of preclinical models for oncology ...

... oncology drug development. However, high costs, long development timelines and steep rates of attrition continue to afflict the drug development ...